IP Library Granted Patent US 8,273,712
Granted Patent B2
US 8,273,712 · App. 12/094,322 · Granted Sep 25, 2012

Promoting wound healing by administering a prostaglandin E and granulocyte-macrophage colony stimulating factor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,273,712
App. No.
12/094,322
Granted
Sep 25, 2012
Kind
B2
Abstract

A method of promoting healing of a wound in a patient, the method comprising administering to the patient (i) a prostaglandin E (PGE) or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) granulocyte-macrophage colony stimulating factor (GMCSF) or a derivative thereof. Use of (i) a PGE or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) GMCSF or a derivative thereof in the preparation of a medicament for promoting healing of a wound in a patient. A wound dressing, bandage or fibrin glue comprising (i) a PGE or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) GMCSF or a derivative thereof.

Claims (17)

1. A method of promoting healing of a wound in a patient, the method comprising administering to the patient, within the first four days following wounding, (i) a prostaglandin E (PGE) or an agonist thereof and (ii) granulocyte-macrophage colony stimulating factor (GMCSF) or a derivative thereof, wherein the method does not include administering a skin stem cell to the patient and said administering is carried out by applying to the wound a wound dressing or bandage that comprises (i) and (ii).

2. A method according to claim 1 wherein the PGE or agonist thereof is any one of PGE 1 , PGE 2 , 19-hydroxy PGE 1 , 19-hydroxy PGE 2 , 16,16-dimethyl PGE, dinoprostone, misoprostol, alprostadil and limaprost.

3. A method according to claim 1 wherein the GMCSF is human GMCSF having the amino acid sequence of SEQ ID NO: 2, or a naturally occurring variant thereof.

4. A method according to claim 1 wherein the GMCSF is sargramostim or molgramostim.

5. A method according to claim 1 further comprising administering at least one antimicrobial agent to the patient.

6. A method according to claim 5 wherein the antimicrobial agent is an antibacterial agent, an antifungal agent or an antiviral agent.

7. A method according to claim 6 wherein the antibacterial agent is selected from gentamicin, ampicillin, benzypenicillin, benethamine penicillin, benzathine penicillin, phenethicillin, phenoxy-methyl penicillin, procaine penicillin, cloxacillin, flucloxacillin, methicillin sodium, amoxicillin, bacampicillin hydrochloride, ciclacillin, mezlocillin, pivampicillin, talampicillin hydrochloride, carfecillin sodium, piperacillin, ticarcillin, mecillinam, pirmecillinan, cefaclor, cefadroxil, cefotaxime, cefoxitin, cefsulodin sodium, ceftazidime, ceftizoxime, cefuroxime, cephalexin, cephalothin, cephamandole, cephazolin, cephradine, cefpirome, latamoxef disodium, aztreonam, glycylcyclines, chlortetracycline hydrochloride, clomocycline sodium, demeclocydine hydrochloride, doxycycline, lymecycline, minocycline, oxytetracycline, amikacin, framycetin sulphate, neomycin sulphate, netilmicin, tobramycin, colistin, sodium fusidate, fupirocin, polymyxin B sulphate, spectinomycin, vancomycin, teicoplanin, calcium sulphaloxate, sulphametopyrazine, sulphadiazine, sulphadimidine, sulphaguanidine, sulphaurea, capreomycin, metronidazole, tinidazole, cinoxacin, ciprofloxacin, norfloxacin, nitrofurantoin, hexamine, streptomycin, carbenicillin, colistimethate, polymyxin B, furazolidone, nalidixic acid, trimethoprim-sulphamethoxazole, clindamycin, lincomycin, cycloserine, isoniazid, ethambutol, ethionamide, pyrazinamide, meropenem and imipenem.

8. A method according to claim 6 wherein the antifungal agent is selected from miconazole, ketoconazole, itraconazole, fluconazole, amphotericin, flucytosine, griseofulvin, natamycin and nystatin.

9. A method according to claim 6 wherein the antiviral agent is selected from acyclovir, AZT, ddI, amantadine hydrochloride, inosine pranobex and vidarabine.

10. A method according to claim 5 wherein the antimicrobial agent is administered locally to the patient at the site of the wound.

11. A method according to claim 1 further comprising administering an analgesic agent or an anesthetic agent locally to the patient at the site of the wound.

12. A method according to claim 11 wherein the analgesic agent is selected from methylsalicylate, salicylic acid, dyclonine and aloe vera.

13. A method according to claim 11 wherein the anesthetic is selected from benzocaine, lidocaine, xylocalne and butamben picrate.

14. A method according to claim 1 wherein the wound is an external wound.

15. A method according to claim 1 wherein said administering further comprises administering to the patient one or more of an antimicrobial agent, analgesic agent, and anesthetic agent.

16. A method according to claim 15 wherein said administering of (i) the PGE or agonist thereof, and (ii) GMCSF or derivative thereof, is carried out simultaneously with said administering of one or more of the antimicrobial agent, analgesic agent, and anesthetic agent.

17. A method according to claim 1 wherein the wound dressing or bandage further comprises an antimicrobial agent, analgesic agent, or anesthetic agent.

Assignments (1)
CHANGE OF ADDRESS Recorded Mar 21, 2011
From: MEDICAL RESEARCH COUNCIL
To: MEDICAL RESEARCH COUNCIL
Reel/Frame 025990/0240 →